董事會會議召開日期 藥捷安康（南京）科技股份有限公司（「本公司」）董事會（「董事會」）茲宣佈，謹定 於2025年8月25日（星期一）舉行董事會會議，藉以（其中包括）(i)考慮及批准本 公司及其附屬公司截至2025年6月30日止六個月之未經審核綜合中期業績及其發 佈；(ii)考慮宣派及派付中期股息（如有）；以及(iii)處理任何其他事項。 承董事會命 藥捷安康（南京）科技股份有限公司 董事長兼首席執行官 吳永謙博士 香港，2025年8月13日 於本公告日期，董事會包括執行董事吳永謙博士及吳笛先生；非執行董事賈中新 女士及易華博士；及獨立非執行董事徐海音女士、鄭哲蘭女士及李書湃先生。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 本公司全體董事及全體監事均出席股東週年大會。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） 於2025年8月4日舉行的股東週年大會的投票表決結果 董事會欣然宣佈，所有提呈決議案已於2025年8月4日舉行的股東週年大會上獲 股東以投票方式正式通過。 茲提述藥捷安康（南京）科技股份有限公司（「本公司」）日期為2025年7月11日的股 東週年大會通告（「通告」）及通函（「通函」）。除文義另有所指外，本公告所用詞彙 與通函所界定者具有相同涵義。 董事會欣然宣佈，通告所載所有提呈決議案已於股東週年大會上獲股東以投票方 式正式通過。 於股東週年大會日期，本公司已發行股份總數為396,897,633股，其中301,666,673 股為H股，95,230,960股為非上市股份。所有股份持有人有 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥捷安康 (南京 )科技股份有限公司 呈交日期: 2025年8月4日 FF301 第 1 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02617 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,666,673 | RMB | | 1 RMB | | 301,666,673 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,666,673 | RMB | | 1 RMB | | 301,666,673 | ...

Group 1: Investment Opportunities - Vili Zhibo-B (HK02617) has launched its IPO with a subscription rate of approximately 178.91 times on the first day, indicating strong investor confidence in its prospects [1] - Aux Group has refiled its listing application with the Hong Kong Stock Exchange, aiming to enhance brand influence and expand into international markets [2] - Fourth Paradigm (HK06682) plans to place 25.9 million shares at a subscription price of HKD 50.50 per share, raising approximately HKD 1.306 billion for investment in emerging fields like AI and blockchain [3] - October Rice Field (HK09676) expects an adjusted net profit of at least HKD 283 million for the six months ending June 30, 2025, representing a growth of no less than 90% year-on-year due to product innovation and improved sales channels [4] Group 2: Market Performance - The Hang Seng Index closed at 24,498.95, down 0.08% on July 17 [5] - The Hang Seng Tech Index increased by 0.56% to 5,448.85 [5] - The National Enterprises Index fell by 0.09% to 8,853.10 [5]

Group 1 - The stock of Yaojie Ankang-B (02617) rose over 10%, reaching a new high of 30.7 HKD, which is an increase of over 130% from the IPO price of 13.15 HKD [1] - As of the report, the stock was up 8.83% at 30.2 HKD, with a trading volume of 24.18 million HKD and a market capitalization that briefly exceeded 12 billion HKD [1] - Yaojie Ankang announced that its self-developed multi-target kinase inhibitor, TT-00420, received Fast Track designation from the FDA for the treatment of metastatic castration-resistant prostate cancer [1] Group 2 - According to Frost & Sullivan, the global CCA drug market is expected to reach 2 billion USD by 2024, with a compound annual growth rate (CAGR) of 16.2% from 2019 to 2024 [2] - The market is projected to grow to 3.2 billion USD by 2027, with a CAGR of 17.1% from 2024 to 2027, and further increase to 4.6 billion USD by 2030, with a CAGR of 12.8% from 2027 to 2030 [2] - The company is a leader in the niche industry, with Tinengotinib being the first and only FGFR inhibitor entering the registration clinical stage for treating recurrent or refractory cholangiocarcinoma patients [2]

Core Insights - The FDA has granted fast track designation to Tinengotinib (TT-00420) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1][2] - mCRPC is a significant cause of mortality in prostate cancer patients, with global incidence projected to rise from 180,500 cases in 2019 to 209,300 cases in 2024 due to aging populations [1] - Tinengotinib is a multi-target kinase inhibitor in Phase III trials, showing potential efficacy in treating various solid tumors [1][2] Company Developments - Tinengotinib is the first and only drug with clinical efficacy evidence targeting both FGFR and JAK pathways for mCRPC [2] - In early-phase clinical trials, Tinengotinib demonstrated an overall response rate (ORR) of 46% and a disease control rate (DCR) of 85%, with over 90% of patients experiencing tumor volume reduction [2] - The successful fast track designation for Tinengotinib highlights the company's efficient clinical and regulatory execution capabilities [2]

Core Viewpoint - The article highlights the recent IPO of three companies on the Hong Kong Stock Exchange, with a particular focus on药捷安康, which experienced a significant stock price increase on its debut despite being in a loss-making position and lacking approved products for commercial sale [1][2]. Group 1: Company Overview - 药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for cancer, inflammation, and cardiovascular metabolic diseases [1]. - The company was founded in 2014 and had previously attempted to list on the Hong Kong Stock Exchange in 2021 but did not proceed [3]. Group 2: IPO Details - 药捷安康 priced its shares at HKD 13.15, issuing 15.281 million shares, with a public offering oversubscription rate of 3,419.87 times [2]. - The company raised approximately HKD 1.61 billion from the IPO, with plans to allocate 90% of the net proceeds to fund a multi-regional Phase III clinical trial for its core product, Tinengotinib [4]. Group 3: Financial Performance - 药捷安康 reported cumulative losses exceeding HKD 618 million over the past two years, with projected revenues of HKD 1.18 million in 2023 and zero in 2024, alongside significant R&D costs [3]. - The company has utilized about 72% of the funds raised from previous investments prior to the IPO [3]. Group 4: Future Plans - Following the IPO, 药捷安康 aims to accelerate its internationalization and commercialization efforts, including the establishment of an internal commercial team in China [2].

Core Viewpoint - Yaojie Ankang (Nanjing) Technology Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, with its stock closing at HKD 23.50, representing a 78.71% increase from its initial offering price of HKD 13.15 [1][4]. Group 1: Share Issuance and Financials - The total number of shares issued by Yaojie Ankang is 15,281,000, with 3,057,000 shares allocated for public offering in Hong Kong and 12,224,000 shares for international offering [2]. - The total proceeds from the share issuance amount to HKD 200.95 million, with net proceeds of HKD 161.34 million after deducting estimated listing fees of HKD 39.61 million [4][5]. - The company currently has 396,897,633 shares outstanding at the time of listing [2]. Group 2: Use of Proceeds - Approximately 90% of the net proceeds will be allocated to the research and development of the company's core product, Tinengotinib, while the remaining 10% will be used for general working capital and corporate purposes [5]. Group 3: Company Overview and Financial Performance - Yaojie Ankang is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [5]. - The company reported no revenue for 2023 and projected revenue of RMB 1.2 million for 2024, with no products currently approved for commercial sale [6]. - The company incurred losses of RMB 343.4 million in 2023 and RMB 274.6 million in 2024, totaling RMB 618 million over the two years, primarily due to high R&D costs and management expenses [6][7].

Core Viewpoint - The Hang Seng Index (HSI) experienced a low opening but rallied to close approximately 0.7% higher, driven by strong performance in the semiconductor sector and a rebound in the pharmaceutical sector [1] Market Performance - The HSI closed at 23,689.13 points, up 0.67%, while the Hang Seng Tech Index rose by 1.05% to 5,187.01 points [1] - The total market turnover reached 1,985.91 million HKD, a decrease from the previous trading day's turnover of 2,224.23 million HKD [1] Sector Performance - The semiconductor sector led the market with significant gains, while the pharmaceutical sector showed a strong rebound [1] - New consumption and automotive sectors also experienced a low opening but managed to recover throughout the day [1] Notable Stocks - Semiconductor company SMIC (00981.HK) saw a rise of 4.56% [1] - Li Auto (02015.HK) increased by 5.49% [1] - Pharmaceutical company Jiateng Pharmaceutical (02617.HK) surged by 78.71% [1] - Sanhua Intelligent Control (02050.HK) experienced a slight decline of 0.13% on its first trading day [1]

Core Viewpoint - The company,药捷安康, is set to launch an IPO with a global offering of 15.281 million H-shares at a price of HKD 13.15 per share, aiming to raise approximately HKD 201 million, with listing expected on June 23, 2025 [1][3]. Company Overview -药捷安康, established in April 2014, focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular diseases [5]. - The company has developed a pipeline that includes one core product and five clinical-stage candidates, along with one preclinical candidate [5]. Financial Highlights - The total amount raised from cornerstone investors is approximately HKD 149 million, with notable investors including Jiangbei Pharmaceutical and Kangfang Biotech [3]. - For the years 2023 and 2024, the company reported net losses of approximately RMB 343.39 million and RMB 274.61 million, respectively [7]. Research and Development - The core product, Tinengotinib, is a multi-target kinase inhibitor currently undergoing two pivotal clinical trials for cholangiocarcinoma [5][6]. - The R&D costs for 2023 and 2024 are estimated at RMB 344.75 million and RMB 244.00 million, representing 89.8% and 83.6% of total operating expenses, respectively [6].